To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Prevention of COVID-19 infection to severe pneumonea or ARDS

Inclusion Criteria:

• Signed informed consent
• Male or female age 19 years or older
• Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion Criteria:

• Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia
• Pregnant or nursing at the time of signing informed consent
• Known sensitivity to any study medication
• Unwilling or unable to complete study diary
• Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol